Mary Caffrey

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

Rising early-onset colorectal cancer rates among young adults highlight the urgent need to explore lifestyle, genetics, and environmental factors driving this trend.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.

MATTERHORN shows durvalumab enhances survival in early-stage gastric and GEJ cancer, revolutionizing treatment approaches for patients.

Molecular testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, significantly improving disease-free survival rates post-surgery.

An ASCO session on quality services shows how patient and caregiver engagement is crucial to gain better outcomes and cost savings from symptom monitoring efforts.

Studies presented at ASCO reveal promising treatments for triple-negative and ER-positive breast cancer, highlighting the benefits of sacituzumab govitecan and vepdegestrant.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

ASCO and Google Cloud unveil an AI tool that streamlines access to clinical guidelines, enhancing decision-making for oncologists in patient care.

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable seniors.

According to news reports, Biden's cancer is aggressive and has reached the bones.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses some of the recent trends in cancer detection, screenings, and resource utilization in community oncology.

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial treatment, as well as the changing landscape of multiple myeloma treatment.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated with a daratumumab quadruplet regimen.

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.

Results presented on Tuesday at the American Association for Cancer Research annual meeting include data on the combined use of tissue and liquid biopsy, as well as a framework for evaluating multicancer early detection testing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.